MedTrace Logo

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

NCT02044120 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-01-12

No results posted yet for this study

Summary

The purpose of this study is to define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide and/or irinotecan in patients with pre-treated incurable Ewing sarcoma.

Conditions

  • Ewing Sarcoma

Interventions

DRUG

niraparib

DRUG

Temozolomide

DRUG

Irinotecan

Sponsors & Collaborators

  • Sarcoma Alliance for Research through Collaboration

    lead OTHER

Principal Investigators

  • Rashmi Chugh, MD · University of Michigan

  • Sandra Strauss, MBBS, PhD · University College London, Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02044120 on ClinicalTrials.gov